Daniel, Dylan <br/><br/>
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.  [electronic resource] 

 -  Blood  Dec 2007 
 - 4037-46 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0006-4971 
<br/><br/><label>Standard No.: </label>10.1182/blood-2007-02-076075  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--pharmacology<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antibody Formation--drug effects<br/>Antineoplastic Agents--agonists<br/>Apoptosis--drug effects<br/>Cell Line, Tumor<br/>Complement System Proteins--metabolism<br/>Drug Resistance, Neoplasm--drug effects<br/>Drug Synergism<br/>Female<br/>Humans<br/>Killer Cells, Natural--metabolism<br/>Lymphocyte Depletion<br/>Lymphoma, Non-Hodgkin--drug therapy<br/>Mice<br/>Mice, Inbred ICR<br/>Mice, SCID<br/>Receptors, TNF-Related Apoptosis-Inducing Ligand--antagonists & inhibitors<br/>Receptors, Tumor Necrosis Factor--antagonists & inhibitors<br/>Recombinant Proteins--agonists<br/>Rituximab<br/>TNF-Related Apoptosis-Inducing Ligand--agonists<br/>Transplantation, Heterologous<br/>Xenograft Model Antitumor Assays